BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 11788979)

  • 1. Opportunity costs and uncertainty in the economic evaluation of health care interventions.
    Sendi P; Gafni A; Birch S
    Health Econ; 2002 Jan; 11(1):23-31. PubMed ID: 11788979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing a portfolio of health care programs in the presence of uncertainty and constrained resources.
    Sendi P; Al MJ; Gafni A; Birch S
    Soc Sci Med; 2003 Dec; 57(11):2207-15. PubMed ID: 14512250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane.
    Sendi PP; Briggs AH
    Health Econ; 2001 Oct; 10(7):675-80. PubMed ID: 11747050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revisiting the decision rule of cost-effectiveness analysis under certainty and uncertainty.
    Sendi P; Al MJ
    Soc Sci Med; 2003 Sep; 57(6):969-74. PubMed ID: 12878098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness league tables: think of the fans.
    Drummond M; Mason J; Torrance G
    Health Policy; 1995 Mar; 31(3):231-8. PubMed ID: 10142619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be?
    Birch S; Gafni A
    J Health Econ; 1992 Oct; 11(3):279-96. PubMed ID: 10122540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Portfolio evaluation of health programs: a reply to Sendi et al.
    Bridges JF; Terris DD
    Soc Sci Med; 2004 May; 58(10):1849-51. PubMed ID: 15020002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using cost-effectiveness/cost-benefit analysis to allocate health resources: a level playing field for prevention?
    Phillips KA; Hotlgrave DR
    Am J Prev Med; 1997; 13(1):18-25. PubMed ID: 9037338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Portfolio theory and the alternative decision rule of cost-effectiveness analysis: theoretical and practical considerations.
    Sendi P; Al MJ; Gafni A; Birch S
    Soc Sci Med; 2004 May; 58(10):1853-5. PubMed ID: 15020003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of cost-effectiveness analysis to multiple products: a practical guide.
    Bala MV; Zarkin GA
    Am J Manag Care; 2002 Mar; 8(3):211-8. PubMed ID: 11915971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications of basing health-care resource allocations on cost-utility analysis in the presence of externalities.
    Labelle RJ; Hurley JE
    J Health Econ; 1992 Oct; 11(3):259-77. PubMed ID: 10122539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporating Affordability Concerns Within Cost-Effectiveness Analysis for Health Technology Assessment.
    Lomas JRS
    Value Health; 2019 Aug; 22(8):898-905. PubMed ID: 31426931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis.
    Groot Koerkamp B; Hunink MG; Stijnen T; Hammitt JK; Kuntz KM; Weinstein MC
    Med Decis Making; 2007; 27(2):101-11. PubMed ID: 17409361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Building uncertainty into cost-effectiveness rankings: portfolio risk-return tradeoffs and implications for decision rules.
    O'Brien BJ; Sculpher MJ
    Med Care; 2000 May; 38(5):460-8. PubMed ID: 10800973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the estimation of cost-effectiveness ratios.
    Johannesson M
    Health Policy; 1995 Mar; 31(3):225-9. PubMed ID: 10142618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mathematical programming for the efficient allocation of health care resources.
    Stinnett AA; Paltiel AD
    J Health Econ; 1996 Oct; 15(5):641-53. PubMed ID: 10164046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of programmes aiming at eradicating infectious diseases.
    Gyldmark M; Alban A
    Health Policy; 1998 Jul; 45(1):69-79. PubMed ID: 10183014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Portfolio theory and cost-effectiveness analysis: a further discussion.
    Sendi P; Al MJ; Rutten FF
    Value Health; 2004; 7(5):595-601. PubMed ID: 15367254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measuring the social importance of concentration or dispersion of individual health benefits.
    Rodríguez-Míguez E; Pinto-Prades JL
    Health Econ; 2002 Jan; 11(1):43-53. PubMed ID: 11788981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal allocation of resources over health care programmes: dealing with decreasing marginal utility and uncertainty.
    Al MJ; Feenstra TL; Hout BA
    Health Econ; 2005 Jul; 14(7):655-67. PubMed ID: 15678518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.